Florida |
000-29819
|
58-2349413
|
||
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.) | ||
850 Third Avenue
Suite 1801
New York, New York
|
10022 | |
(Address of principal executive offices)
|
(Zip Code)
|
(Former name or former address, if changed since last report)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
●
|
2,500,000 options will vest and become exercisable immediately on November 27, 2012 (the “Zeldis Effective Date”);
|
●
|
7,500,000 options will vest and become exercisable in three equal annual installments, with the first installment becoming exercisable on the first anniversary of the Zeldis Effective Date, the second installment becoming exercisable on the second anniversary of the Zeldis Effective Date and the third installment becoming exercisable on the third anniversary of the Zeldis Effective Date;
|
●
|
2,500,000 options will vest and become exercisable immediately upon the closing of a transaction, pursuant to which the Company (i) acquires control of, or (ii) enters into a partnership, joint venture or similar arrangement with one or more entities engaged in the wound care, topical delivery or systemic therapeutics business or any other business line of the Company (“Strategic Transaction”), and such Strategic Transaction is approved by the Board;
|
●
|
5,000,000 options will vest and become exercisable immediately upon the listing of the Common Stock on a U.S. national securities exchange (e.g., NYSE MKT LLC, The Nasdaq Stock Market LLC , the New York Stock Exchange) by September 30, 2013; and
|
●
|
2,500,000 options will vest and become exercisable immediately upon the closing of a sale, spin-off or other disposition of either the Company’s wound care or bioartificial liver system businesses by December 31, 2013 or at a target date specified by the Board after considering the current business environment.
|
Exhibit Number
|
Description
|
|
Press Release dated November 29, 2012
|
||
ALLIQUA, INC.
|
|||
Dated: December 3, 2012
|
By:
|
/s/ Steven Berger | |
Name: Steven Berger | |||
Title: Chief Financial Officer | |||
Exhibit Number
|
Description
|
|
Press Release dated November 29, 2012
|
||